pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Electra Therapeutics Inc

updated 3mo ago
Website ↗
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 3: 1
1Phase 3
Phase 3
ipsoprubart
Hemophagocytic Lymphohistiocytosis

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)recruitingn=156
  • phase1A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)recruitingn=84
  • phase1Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteerscompletedn=91
🐶 Hiring Signal
No open roles indexed yet — view Electra Therapeutics Inc jobs →

News

  • Star adds $200M after spinout successes
    Following exits for its subsidiaries Electra Therapeutics and Vega Therapeutics, Star is now mining for a new drug prospect.
    biopharma_dive · 27d ago
  • ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
    Two RNA biotechs, ADARx Pharmaceuticals and City Therapeutics, are taking advantage of the IPO frenzy, which has led to a total of 27 newly public biotechs so far this year.
    biospace · 1mo ago
  • Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
    Novo plans to hit $23B in revenue by 2035, has further reduced its workforce by 4,000 and is boosting manufacturing capacity for its Wegovy pill, but investors are unconvinced it will be enough to…
    biospace · 1mo ago
  • Electra lights up with $350M IPO for pivotal immune-disease drug development
    Electra Therapeutics has exceeded its initial fundraising plans as it becomes the 26th biotech to debut publicly this year and outlines pivotal development plans for its monoclonal antibody ipsopru…
    biospace · 2mo ago
  • This week in charts: GSK’s China deals, the $300M IPO club and selling the news
    The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall Street analysts and a closer look at an industry-leading partnership streak.
    biopharma_dive · 2mo ago
  • Inflammation biotech Electra charges up with $350M from upsized IPO
    Electra Therapeutics is the latest biotech to overshoot its own IPO expectations this year, with the inflammation-focused company bringing in $350 million from this morning’s Nasdaq listing.
    fiercebiotech · 2mo ago
  • Electra's $350M IPO will help it become a commercial biotech
    Electra Therapeutics became the 21st biotech of 2026 to go through with an IPO after pricing its $350 million Nasdaq debut on Thursday evening. The Bay Area biotech will use the ...
    endpoints · 2mo ago
  • Electra amasses $350M in biotech’s latest big IPO
    Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to BioP…
    biopharma_dive · 2mo ago
  • Electra aims for nearly $300M IPO; Enhertu's Phase 3 lung cancer success
    Plus news about Lilly, Cellectis, Tyra, Shennon and QL Biopharm. Electra Therapeutics eyes $297M IPO: The Sanofi-backed biotech hopes to kick off the post-Labor Day IPO train with a nearly $300 mil…
    endpoints · 2mo ago
  • Electra aims for $342M IPO to power inflammatory drug’s push through phase 3
    Electra Therapeutics is hoping to raise up to $341.9 million from an IPO in order to power the clinical development of its inflammatory disorder drug, ipsoprubart.
    fiercebiotech · 2mo ago
view all news mentions →
identifiers
source
globaldata
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?